Q-omics provides the consensus-scored TUBBP8 profile across patient tissues and cancer cell-line models. TUBBP8 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, TUBBP8 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, TUBBP8 RNA expression shows 6,645 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, and STAD as cancer lineages where TUBBP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBBP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBBP8 survival associations across molecular data types. TUBBP8 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBBP8 RNA expression–survival associations across cancer types. High TUBBP8 expression shows unfavorable associations in DLBC, PCPG, SKCM, LGG, MESO and KIRC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for TUBBP8 RNA expression.
This table summarizes TUBBP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TUBBP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBBP8 shows lower tumor expression in STAD and KIRP and higher tumor expression in HNSC and KIRC. The STAD box plot shows higher TUBBP8 RNA expression in normal versus tumor tissue (log2 FC = −0.230, t-test p = .028).
This table shows molecular features associated with TUBBP8 in patient tissues and cancer cell lines. In patient samples, TUBBP8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
